biostudies-literatureUnknown7(4)Schmitz-Winnenthal FHVAXIMM AGVXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated <i>Salmonella</i> typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation trial in advanced pancreatic cancer patients demonstrated safety, immunogenicity and transient, T-cell response-related anti-angiogenic activity of four priming vaccinations applied within one week. We here evaluated whether monthly boost vaccinations are safe and can sustain increased frequencies of vaccine-specific T cells. Patients with advanced pancreatic cancer were randomly assigned at a ratio of 2:1 to priming with VXM01 followed by up to six monthly boost vacciOncoimmunologye1303584https://www.ebi.ac.uk/biostudies/studies/S-EPMC5889207biostudies-literatureA phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.PMC5889207Springer MWieckowski SKnebel PKoc RHaefeli WESpringfeld CBuchler MWLubenau HPodola LMikus GGrenacher LSchmitz-Winnenthal FHBucur MHohmann NBeckhove PSchmidt TBreiner KMKeller AVFriedrich TfalseA phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.VXM01 is a first-in-kind orally applied tumor vaccine based on live attenuated <i>Salmonella</i> typhi carrying an expression plasmid encoding VEGFR2, an antigen expressed on tumor vasculature and a stable and accessible target for anti-angiogenic intervention. A recent randomized, placebo-controlled, phase I dose-escalation trial in advanced pancreatic cancer patients demonstrated safety, immunogenicity and transient, T-cell response-related anti-angiogenic activity of four priming vaccinations applied within one week. We here evaluated whether monthly boost vaccinations are safe and can sustain increased frequencies of vaccine-specific T cells. Patients with advanced pancreatic cancer were randomly assigned at a ratio of 2:1 to priming with VXM01 followed by up to six monthly boost vacci2018-01-01T00:00:00Z20182026-04-07T23:22:49.723Z2019-03-26T22:37:18ZS-EPMC58892072963271010.1080/2162402X.2017.130358410.1080/2162402x.2017.1303584